Evaluating diagnostic strategies for early detection of cancer: the CanTest framework

[1]  Martin Eklund,et al.  The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. , 2018, European urology.

[2]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[3]  J. Emery,et al.  Reimagining the diagnostic pathway for gastrointestinal cancer , 2018, Nature Reviews Gastroenterology & Hepatology.

[4]  Wojtek Wiercioch,et al.  Decision-making about healthcare related tests and diagnostic strategies : A review of methodological and practical challenges , 2017 .

[5]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[6]  H. Schünemann,et al.  Decision making about healthcare-related tests and diagnostic test strategies. Paper 1: a new series on testing to improve people's health. , 2017, Journal of clinical epidemiology.

[7]  Matthew J. Thompson,et al.  Common evidence gaps in point-of-care diagnostic test evaluation: a review of horizon scan reports , 2017, BMJ Open.

[8]  H. Welch,et al.  New diagnostic tests: more harm than good , 2017, British Medical Journal.

[9]  P. Prorok,et al.  Prostate Cancer Screening - A Perspective on the Current State of the Evidence. , 2017, The New England journal of medicine.

[10]  S. Sharp,et al.  The spectrum effect in tests for risk prediction, screening, and diagnosis , 2016, British Medical Journal.

[11]  B. Weigl,et al.  More Than Just Accuracy: A Novel Method to Incorporate Multiple Test Attributes in Evaluating Diagnostic Tests Including Point of Care Tests , 2016 .

[12]  Dean F Sittig,et al.  Measuring and improving patient safety through health information technology: The Health IT Safety Framework , 2015, BMJ Quality & Safety.

[13]  J. Wardle,et al.  The expanding role of primary care in cancer control. , 2015, The Lancet. Oncology.

[14]  Hardeep Singh,et al.  Understanding missed opportunities for more timely diagnosis of cancer in symptomatic patients after presentation , 2015, British Journal of Cancer.

[15]  Dean F. Sittig,et al.  Advancing the science of measurement of diagnostic errors in healthcare: the Safer Dx framework , 2015, BMJ quality & safety.

[16]  O. Kucuk,et al.  Cancer biomarkers. , 2015, Molecular aspects of medicine.

[17]  D. Moher,et al.  Scoping reviews: time for clarity in definition, methods, and reporting. , 2014, Journal of clinical epidemiology.

[18]  C. Price,et al.  Anatomy of a value proposition for laboratory medicine. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[19]  Sverre Sandberg,et al.  From biomarkers to medical tests: the changing landscape of test evaluation. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[20]  Karen M Schoelles,et al.  Assessing the Utility of Genetic Tests , 2013, The Journal of ambulatory care management.

[21]  Matthew Thompson,et al.  Evaluating genomic tests from bench to bedside: a practical framework , 2012, BMC Medical Informatics and Decision Making.

[22]  N. Henry,et al.  Cancer biomarkers , 2012, Molecular oncology.

[23]  P. Bossuyt,et al.  Assessing the value of diagnostic tests: a framework for designing and evaluating trials , 2012, BMJ : British Medical Journal.

[24]  G. Gazelle,et al.  A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research. , 2011, Radiology.

[25]  P. Febbo,et al.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  H. Burstein.  Beaten at the Alamo by the Europeans. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[27]  O. Mekel,et al.  The Contribution of Health Technology Assessment, Health Needs Assessment, and Health Impact Assessment to the Assessment and Translation of Technologies in the Field of Public Health Genomics , 2010, Public Health Genomics.

[28]  Development and description of GETT: a Genetic testing Evidence Tracking Tool , 2010, Clinical chemistry and laboratory medicine.

[29]  Jeroen G Lijmer,et al.  Proposals for a Phased Evaluation of Medical Tests , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  S. Teutsch,et al.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.

[31]  Kathryn A. Phillips,et al.  Diagnostics and biomarker development: priming the pipeline , 2006, Nature Reviews Drug Discovery.

[32]  H. Arksey,et al.  Scoping studies: towards a methodological framework , 2005 .

[33]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[34]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[35]  David Atkins,et al.  Current methods of the U.S. Preventive Services Task Force , 2001 .

[36]  Dennis G. Fryback,et al.  The Efficacy of Diagnostic Imaging , 1991, Medical decision making : an international journal of the Society for Medical Decision Making.